<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://stocktwits.com/sitemap/rss_feed.xml</title><link>https://stocktwits.com/sitemap/rss_feed.xml</link><description>Individual feed output.</description><lastBuildDate>Fri, 23 Jan 2026 11:02:47 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Why Did MAAS Stock Gain Over 9% Today?</title><link>https://stocktwits.com/news-articles/markets/equity/why-did-maas-stock-gain-today/cmyRJjbR4g8</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture3.png</image_url><description>Maase will pay roughly RMB1.1 billion ($157 million) to secure 100% of Times Good’s equity, which controls the Huazhi Group.</description><pubDate>Fri, 23 Jan 2026 15:52:45 GMT</pubDate></item><item><title>Spot Silver Touches $100 An Ounce For First Time Ever, Gold Within Striking Distance Of $5,000 Amid Lingering Geopolitical Tensions</title><link>https://stocktwits.com/news-articles/markets/equity/silver-price-touch-100-gold-price-within-5000/cmyRJKbR4gF</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture7.png</image_url><description>Silver futures maturing in March soared by nearly 4% to $100.06.</description><pubDate>Fri, 23 Jan 2026 15:50:59 GMT</pubDate></item><item><title>Amaze Announces Expanded Partnership with Contend to Scale the Next Generation of Creator-Led Commerce</title><link>https://stocktwits.com/news-articles/business/others/amaze-announces-expanded-partnership-with-contend-to-scale-the-next-generation-of-creator-led-commerce/cmyR7o0R4gl</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture8.png</image_url><description></description><pubDate>Fri, 23 Jan 2026 15:20:48 GMT</pubDate></item><item><title>IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz</title><link>https://stocktwits.com/news-articles/markets/equity/ibrx-stock-volatility-after-immunitybio-phase-2-glioblastoma-trial-update/cmyR7VnR4gk</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture5.png</image_url><description>ImmunityBio stated that it has not yet achieved median survival in patients receiving Anktiva + CAR-NK treatment in the trial.</description><pubDate>Fri, 23 Jan 2026 15:18:11 GMT</pubDate></item><item><title>Intel Draws Mixed Street Reaction After Strong Q4 But Cautious 2026 Outlook</title><link>https://stocktwits.com/news-articles/markets/equity/intel-draws-mixed-street-reaction-after-strong-q4-but-cautious-2026-outlook/cmyR7jNR4gj</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture1.png</image_url><description>UBS raised its target to $52 from $49, with a ‘Neutral’ rating, citing supply bottlenecks and structural limitations that may constrain Intel’s AI gro...</description><pubDate>Fri, 23 Jan 2026 15:14:37 GMT</pubDate></item></channel></rss>